Categories
Tags
Abbott Advertising AstraZeneca Barack Obama Biotechnology and Pharmaceuticals Breast cancer Bristol Myers Squibb business Cancer Clinical trial Conditions and Diseases Deal Eli Lilly European Commission European Union FDA Food and Drug Administration Genentech generics GlaxoSmithKline Google GSK HBA Health Health care Johnson & Johnson layoffs Lilly Margaret Hamburg Marketing Merck Novartis Pfizer Pharma Pharmaceutical drug pharmaceutical industry Research and development Roche Sanofi-Aventis Schering Plough social media Twitter U.S. Food and Drug Administration United States Wyeth
Technology News
BioPharm News- Shire Gains European Approval for its Gaucher Disease Treatment
- Mtech Bioprocess Scale-Up Facility to Double in Staff and Size
- ImClone Closes Plant in New Jersey, Consolidating Erbitux Manufacture
- EMA and FDA Seek Applicants for Joint GMP Inspections
- ATMI Expands Bloomington, Minnesota Manufacturing Facility
Clinical Trials News- CRF Health Achieves EXACT ePRO Vendor Certification for Windows Mobile Systems
- ACR Image Metrix Establishes Global Presence
- BioPharm Systems Named to the 2010 Inc. 500|5000 List of Fastest-Growing Companies in the U.S.
- CRF Health Doubles North American Headquarters
- Oracle Completes Acquisition of Phase Forward
Blogroll
-
Meta
Tag Archives: Deal
Merck/Schering-Plough Merger Highlights (Update 1)
Merck and Schering-Plough’s CEOs are giving a run down of the benefits of the $41.1 billion merger, announced this morning, in a conference call with investors. Here are some of the highlights:
• Total price of the sale will be $41.1 billion or $23.6 per Schering share.
• This deal is structured as a reverse merger with [...]
Posted in Deals, Strategy Also tagged Johnson & Johnson, Merck, Merger, Remicade, Schering Plough, Vytorin 4 Comments
Schering-Plough to Merge with Merck for $41.1 Billion
Merck’s Richard T. Clark
Image via Wikipedia
Merck announced, a little over an hour ago, that it had signed an agreement with Schering-Plough’s board of directors to merge the two companies under the Merck name.
The stock and cash transaction is worth over $41 billion with Schering shareholders receiving $10.50 per share in cash and 0.5767 of a [...]
Astellas Keeps After CV Therapeutics
Astellas bid for CV Therapeutics turned hostile this morning when the Japanese drug firm offered $1 billion dollars for the company directly to shareholders.
The CVT board rejected Astellas’s second proposal last Friday stating that the Astellas proposal undervalued the company and is not in the best interest of the shareholders.
In a press release issued this [...]
Posted in Deals Also tagged Astellas, CV Therapeutics, hostile, Offer, Pharma, sale, stockholders Leave a comment
Roche Unsweetens Genentech Pot and Takes it to the Shareholders
Image by Getty Images via Daylife
Roche wants Genentech and it’s sick of waiting for a deal.
Six months after a special committee for the biotech firm’s board of directors rejected Roche’s offer of $43.7 billion or $89 a share, Roche has switched gears and dropped the offer to $86.50 per share and is taking negotiations to [...]
Posted in Deals Also tagged Add new tag, Genentech, Hoffmann–La Roche, Negotiate, Nutley New Jersey 1 Comment

Roche and Genentech Seal the Deal
for $46.8 Billion